This study is open to adults who are at least 18 years old and have: - A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or - A confirmed liver disease called metabolic-associated steatohepatitis (MASH) - BMI of 27 kg/m2 or more or - ...
We've found 11 total result s for "Liver Diseases".
This study is open to adults who are at least 18 years old living with obesity and have: - a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and - moderate or advanced liver fibrosis People wit...
Age: 18 years - 66+
Gender: All
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of am...
- Ornithine Carbamoyltransferase Deficiency Disease
- Urea Cycle Disorders, Inborn
- Amino Acid Metabolism, Inborn Errors
- Brain Diseases
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Central Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Hyperammonemia
- Liver Diseases
- Metabolic Diseases
- Metabolism, Inborn Errors
- Nervous System Diseases
Age: 24 hours - 7 months
Gender: Male
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
- Carcinoma, Hepatocellular
- Fibrosis
- Liver Neoplasms
- Digestive System Neoplasms
- Liver Diseases
- Fatty Liver
Age: 18 years - 66+
Gender: All
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing clinical outcomes in patients undergoing liver transplantation with ex-vivo liver prese...
Age: 18 years - 66+
Gender: All
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticost...
Age: 1 year - 18 years
Gender: All
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity...
Age: 18 - 80 years
Gender: All
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing li...
Age: 18 years - 66+
Gender: All
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for screening of liver cancer. Blood markers will be evaluated to determine their corre...
Age: 18 years - 66+
Gender: All